View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Jan. 3 (HealthDay News) -- The anticoagulant Eliquis (apixaban) has been approved by the U.S. Food and Drug Administration to help prevent stroke and dangerous blood clots in people with atrial fibrillation that isn't caused by a heart valve problem.
Eliquis was evaluated in a clinical study of more than 18,000 people. People who took Eliquis had fewer strokes than those who took warfarin, the FDA said. As with similar drugs, the most frequent serious reaction to Eliquis was significant bleeding, the agency added.
Eliquis should not be taken by people with prosthetic heart valves, or by people whose atrial fibrillation is caused by a heart valve problem, the FDA said.
The drug is produced by Bristol-Myers Squibb, based in Princeton, N.J.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top